Autoimmune disease prevalence is rising steadily, and so is the need to for diagnosis and treatment options. The use of biologics to treat autoimmunity is especially effective but warrants good immune monitoring to ensure safety and unravel mechanisms of action.

We have experts in many types of autoimmune diseases such as Rheumathoid Arthritis (RA), Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD) and more. We offer a scala of services that can help develop therapies to treat autoimmune disease. Whether it is cell, cytokine or antibody based we are happy to discuss options.

• (Spectral) Flow Cytometry
• Mass Cytometry
• Cytokine analysis (ELISA, MSD, CBA, ELIspot, ICS)
• MoDC generation (Innate Immune Cells)
• Antigen specific T cell analysis

References

van den Berg SPH, Toorop AA, Hooijberg F, Wolbink G, Voelkner NMF, Gelissen LMY, Killestein J, van Kempen ZLE, Dorlo TPC, Rispens T. Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis. CPT Pharmacometrics Syst Pharmacol. 2025 Mar 20. doi: 10.1002/psp4.70014. Epub ahead of print. PMID: 40110747.

van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies–Effects on treatment and immunogenicity. MAbs. 2015;7(4):662-71. doi: 10.1080/19420862.2015.1048411. PMID: 25962087; PMCID: PMC4623040.

Toorop AA, Hogenboom L, Bloem K, Kocyigit M, Commandeur NWM, Wijnants A, Lissenberg-Witte BI, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J, van Kempen ZLE. Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):487-493. doi: 10.1136/jnnp-2022-330793. Epub 2023 Jan 24. PMID: 36693720.